Holen Sie sich die Stockscreener-App
12.12
0.17%
0.02
Vorhandelsmarkt:
12.00
-0.12
-0.99%
Schlusskurs vom Vortag:
$12.10
Offen:
$12.17
24-Stunden-Volumen:
430.14K
Relative Volume:
0.43
Marktkapitalisierung:
$540.09M
Einnahmen:
$110.24M
Nettoeinkommen (Verlust:
$-66.44M
KGV:
-8.0206
EPS:
-1.5111
Netto-Cashflow:
$-61.12M
1W Leistung:
+2.54%
1M Leistung:
+22.42%
6M Leistung:
-61.33%
1J Leistung:
-21.09%
1-Tages-Spanne:
$11.74
$12.31
1-Wochen-Bereich:
$11.26
$12.31
52-Wochen-Spanne:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Firmenname
Beta Bionics Inc
Sektor
Branche
Telefon
949-427-7785
Adresse
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
12.12 | 539.20M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | UBS | Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Hold |
| 2026-01-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-10-01 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-06-12 | Eingeleitet | Lake Street | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Neutral |
| 2025-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2025-02-24 | Eingeleitet | BofA Securities | Buy |
| 2025-02-24 | Eingeleitet | Lake Street | Buy |
| 2025-02-24 | Eingeleitet | Leerink Partners | Outperform |
| 2025-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-24 | Eingeleitet | Stifel | Buy |
| 2025-02-20 | Eingeleitet | Ladenburg Thalmann | Neutral |
| 2025-02-20 | Eingeleitet | Robert W. Baird | Neutral |
Alle ansehen
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
BBNX Maintained by Goldman Sachs -- Price Target Lowered to $17. - GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director Jones Christy - Moomoo
Beta Bionics | 4: Statement of changes in beneficial ownership of securities-Director CARNEY SEAN - Moomoo
Beta Bionics director Jones Christy sells $19,880 in stock By Investing.com - Investing.com Nigeria
Beta Bionics director Adam Lezack sells $21,137 in stock By Investing.com - Investing.com India
Beta Bionics director Adam Lezack sells $21,137 in stock - Investing.com
Director at Beta Bionics (BBNX) receives 16,965-share equity award - Stock Titan
Beta Bionics (BBNX) director logs stock grant and 1,998-share sale - Stock Titan
Beta Bionics (BBNX) director receives 16,965-share equity award - Stock Titan
Beta Bionics (BBNX) director receives 16,965-share restricted stock unit grant - Stock Titan
Beta Bionics (BBNX) director awarded 16,965 restricted stock units - Stock Titan
Beta Bionics (BBNX) director gets stock grant, sells 1,998 shares under plan - Stock Titan
Beta Bionics to launch its first insulin patch pump to compete with Insulet - MedTech Dive
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST) - The Globe and Mail
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics | 8-K: Current report - Moomoo
Beta Bionics (NASDAQ: BBNX) investors approve directors and auditor - Stock Titan
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development - Sahm
Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027 - Moomoo
[144] Beta Bionics, Inc. SEC Filing - Stock Titan
Beta Bionics says Mint commercialization expected by end-Q2 2027, subject to FDA clearance - TradingView
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX) - Stock Titan
No-recharge insulin patch pump targets 2027 launch pending FDA clearance - Stock Titan
BBNX Maintains by B of A Securities -- Price Target Lowered to $11.00 - GuruFocus
Beta Bionics Price Target Cut to $11.00/Share From $23.00 by B of A Securities - Moomoo
Beta Bionics, Inc. Stock 12‑Month Price Target Cut to $19.18, Implies 103% Upside - TradingView
BofA Adjusts Price Target on Beta Bionics to $11 From $23 - Moomoo
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Cuts Target Price to $11 - Moomoo
Beta Bionics (BBNX) Stock News, Page 3 - Stock Titan
BBNX Forecast — Price Target — Prediction for 2027 - TradingView
Beta Bionics | SCHEDULE 13G/A: Others - Moomoo
Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics - Stock Titan
RTW Investments reports 2.0M-share stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans - Yahoo Finance
BBNX: Mint patch pump launch set for end of 2027, with pharmacy channel driving growth - TradingView
Farallon and Zone Holdings disclose ownership in Beta Bionics (BBNX) — 13G/A - Stock Titan
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation - Yahoo Finance
Number of shareholders of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Soleus group files 9.8% stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a Potential 93% Upside in Medical Devices - DirectorsTalk Interviews
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $16 to $20 - Moomoo
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock? - MSN
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99 - MSN
Midday Stock Roundup: Tech stocks rally - Orange County Business Journal
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates - MSN
Finanzdaten der Beta Bionics Inc-Aktie (BBNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):